- Expression of IL-27 shown to contribute to upregulation of PD-L1, LAG-3, CTLA-4, and TIGIT
The paper, “IL-27 and TCR Stimulation Promote T Cell Expression of Multiple Inhibitory Receptors,” was published in ImmunoHorizons, a peer-reviewed, open access, online-only journal committed to advancing the knowledge of immunology. Among the findings in the paper, results indicate that the local production of IL-27 at sites of ongoing toxoplasmosis-induced inflammation contributes to expression of PD-L1, LAG-3, CTLA-4, and TIGIT, all key checkpoint proteins in the downregulation of immune responses.
IL-27 is understood to play an important role in turning off an immune response following viral and parasitic infections. Beyond the role of IL-27 in restoring immunostasis,
“This paper is yet another validation of the role of IL-27 as a regulatory cytokine for the upregulation of checkpoint proteins. We are rapidly working toward filing an IND for our IL-27 antibody, SRF388, which we believe will be the first IL-27 antibody for the treatment of cancer. We applaud this additional work in the field and are privileged to work alongside thought leaders such as Dr.
“We have now known for more than 15 years that IL-27 can have remarkable suppressive activities,” said
1 Kuchroo, Et al. Nature 558, pages 454–459 (2018)
SRF388 is a fully human anti-IL-27 antibody. In preclinical studies, treatment with SRF388 was observed to block IL-27 signaling and its downstream immunosuppressive signaling effects. Preclinical combination with a PD-1 inhibitor increased the production of key inflammatory cytokines. SRF388 also demonstrates preclinical anti-metastatic tumor activity.
Under Surface’s collaboration agreement with
ABOUT SURFACE ONCOLOGY
Surface Oncology is an immuno-oncology company developing next-generation antibody therapies focused on the tumor microenvironment with lead programs targeting CD73, CD39, IL-27 and CD47. Surface’s novel cancer immunotherapies are designed to achieve a clinically meaningful and sustained anti-tumor response and may be used alone or in combination with other therapies. The company has a pipeline of seven novel immunotherapies and a strategic collaboration with Novartis focused on up to three next-generation cancer immunotherapies.
For more information, please visit www.surfaceoncology.com
Ten Bridge Communications
Source: Surface Oncology, Inc.